From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target

[Image: see text] Pure antiestrogens, or selective estrogen receptor degraders (SERDs), have proven to be effective in treating breast cancer that has progressed on tamoxifen and/or aromatase inhibitors. However, the only FDA-approved pure antiestrogen, fulvestrant, is limited in efficacy by its low...

Descripción completa

Detalles Bibliográficos
Autores principales: Mottamal, Madhusoodanan, Kang, Borui, Peng, Xianyou, Wang, Guangdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047716/
https://www.ncbi.nlm.nih.gov/pubmed/33869913
http://dx.doi.org/10.1021/acsomega.0c06362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047716/
https://www.ncbi.nlm.nih.gov/pubmed/33869913
http://dx.doi.org/10.1021/acsomega.0c06362

Ejemplares similares